Sarc

ACTIVE

24 Frank Lloyd Wright Dr Ste A3100, 密歇根州沃什特瑙县, 密歇根州, United Statessarctrials.org/about-sarcPrivateEstablished: 2003-01-01

Also known as:

sarcoma alliance for research through collaboration

sarcoma alliance for research through collaboration (sarc)

Clinical Trials

7 active

Approvals

Total approvals

Agencies

Regulatory bodies

Founded

2003

Overview

Trial Phase Distribution

Phase

Trials

Phase 2

65.4%

Phase 1

23.1%

Phase 3

7.7%

Trial Status Distribution

Active, not recruiting

26.9%

Completed

50.0%

No Longer Available

3.9%

Recruiting

7.7%

Terminated

7.7%

Withdrawn

3.9%

Clinical Trials

Trials sponsored by this organization (26)

SARC046: A Phase II Trial of Nab-Sirolimus in Patients With Progressing or Symptomatic Epithelioid Hemangioendothelioma

Phase 2

Recruiting

interventional

Feb 202641 participants

A Phase II Trial of Tebentafusp in HLA-A*02:01 Positive Patients With Advanced Clear Cell Sarcoma

Phase 2

Recruiting

interventional

Oct 202547 participants

SARC044: A Phase II Trial of Bezuclastinib in Combination With Sunitinib in Patients With GIST

Phase 2

Active, not recruiting

interventional

Aug 202440 participants

SARC041: Study of Abemaciclib Versus Placebo in Patients with Advanced Dedifferentiated Liposarcoma

Phase 3

Active, not recruiting

interventional

Nov 2021108 participants

Randomized Controlled Trial comparing two groups of Patients with High-Risk, Localized Soft Tissue Sarcoma of the Extremity: the first one receiving Neoadjuvant Pembrolizumab with Radiotherapy and Adjuvant Pembrolizumab after surgery, and the second one receiving Radiotherapy and surgery, aiming to assess the safety and efficacy profile of Pembrolizumab

Phase 1

Active, not recruiting

Jun 2021110 participants

SARC038: Phase 2 Study of Regorafenib and Nivolumab in Osteosarcoma

Phase 2

Active, not recruiting

interventional

Jun 202148 participants

SARC037: A Phase I/II Study to Evaluate the Safety of Trabectedin in Combination With Irinotecan in Ewing Sarcoma Patients

Phase 1

Completed

interventional

Jan 202137 participants

SARC031: MEK Inhibitor Selumetinib (AZD6244) in Combination With the mTOR Inhibitor Sirolimus for Patients With Malignant Peripheral Nerve Sheath Tumors

Phase 2

Completed

interventional

Oct 201921 participants

Page 1 of 4

Approvals

No approval data available

News

No news articles found

Back to Organizations